The publication serves as an industry roadmap while validating SL Science’s overarching business strategy and research direction. Glioblastoma remains notoriously difficult to treat because tumors ...

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results And Provides Corporate Update. Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett ...

How do you approach clinical trial design for cell and gene therapies? There are a lot of similarities, but also some notable differences that I have encountered the last 15 years working in multiple ...

Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), and the Raiden Science Foundation (RSF), a parent-led rare disease organization, today announced a ...

Gene therapy lung cancer biomarker: Genprex and Roche Diagnostics are partnering to validate a TROP2 test that identifies ...

Children born with severe-to-profound hearing loss caused by mutations in the OTOF gene now have a treatment option that did not exist a week ago. On April 23, 2026, the FDA granted accelerated ...

The development of a pioneering gene therapy to treat a devastating, rare immune disorder led by UCL scientists is set to move into its next phase following promising early pre-clinical studies.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a ...

The FDA’s May 2026 guidance on cell and gene therapies provides for CMC flexibilities while insisting on quality and ...

Zilong Qiu, who is now the subject of an investigation in the death of a 6-year-old girl after the administration of an experimental gene therapy, attends the opening forum for the 2015 Xingyun Award ...